scholarly journals Statistical Disease Progression Modeling in Alzheimer Disease

2020 ◽  
Vol 3 ◽  
Author(s):  
Lars Lau Raket
Keyword(s):  
Alzheimer Disease ◽  
Disease Progression ◽  
Disease Progression Modeling

scholarly journals Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression

2001 ◽  
Vol 58 (3) ◽  
Author(s):  
Martin R. Farlow ◽  
Ann Hake ◽  
John Messina ◽  
Richard Hartman ◽  
Jeffrey Veach ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Disease Progression

scholarly journals Disease Progression in Frontotemporal Dementia and Alzheimer Disease: The Contribution of Staging Scales

2020 ◽  
pp. 089198872094423
Author(s):  
Thaís Bento Lima-Silva ◽  
Eneida Mioshi ◽  
Valéria Santoro Bahia ◽  
Mário Amore Cecchini ◽  
Luciana Cassimiro ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Disease Progression ◽  
Frontotemporal Dementia ◽  
Rating Scale ◽  
Severe Disease ◽  
Primary Progressive Aphasia ◽  
Behavioral Changes ◽  
Clinical Dementia Rating ◽  
Dementia Rating Scale ◽  
Disease Stages

Introduction: There is a shortage of validated instruments to estimate disease progression in frontotemporal dementia (FTD). Objectives: To evaluate the ability of the FTD Rating Scale (FTD-FRS) to detect functional and behavioral changes in patients diagnosed with the behavioral variant of FTD (bvFTD), primary progressive aphasia (PPA), and Alzheimer disease (AD) after 12 months of the initial evaluation, compared to the Clinical Dementia Rating scale−frontotemporal lobar degeneration (CDR-FTLD) and the original Clinical Dementia Rating scale (CDR). Methods: The sample consisted of 70 individuals, aged 40+ years, with at least 2 years of schooling, 31 with the diagnosis of bvFTD, 12 with PPA (8 with semantic variant and 4 with non-fluent variant), and 27 with AD. The FTD-FRS, the CDR, and the 2 additional CDR-FTLD items were completed by a clinician, based on the information provided by the caregiver with frequent contact with the patient. The Addenbrooke Cognitive Examination-Revised was completed by patients. After 12 months, the same protocol was applied. Results: The FTD-FRS, CDR-FTLD, and CDR detected significant decline after 12 months in the 3 clinical groups (exception: FTD-FRS for PPA). The CDR was less sensitive to severe disease stages. Conclusions: The FTD-FRS and the CDR-FTLD are especially useful tools for dementia staging in AD and in the FTD spectrum.

scholarly journals Computational disease progression modeling can provide insights into cancer evolution

Oncoscience ◽  
2020 ◽  
Vol 7 (3-4) ◽  
pp. 21-22
Author(s):  
Steve Goodison ◽  
Mark E. Sherman ◽  
Yijun Sun
Keyword(s):  
Disease Progression ◽  
Cancer Evolution ◽  
Disease Progression Modeling

P1-346: Disease progression modeling of bapineuzumab utilizing Alzheimer's Disability Assessment for Dementia scores

2013 ◽  
Vol 9 ◽  
pp. P284-P284
Author(s):  
Mahesh Samtani ◽  
Steven Xu ◽  
O.J. Adedokun ◽  
Kaori Ito ◽  
Brian Corrigan ◽  
...  
Keyword(s):  
Disease Progression ◽  
Disability Assessment ◽  
Disease Progression Modeling

Measuring Alzheimer Disease Progression with Transition Probabilities: Estimates from NACC-UDS

2012 ◽  
Vol 9 (9) ◽  
pp. 1050-1058 ◽  
Author(s):  
D. Eldon Spackman ◽  
Srikanth Kadiyala ◽  
Peter J. Neumann ◽  
David L. Veenstra ◽  
Sean D. Sullivan
Keyword(s):  
Alzheimer Disease ◽  
Disease Progression ◽  
Transition Probabilities
Sign in / Sign up

Export Citation Format

Share Document